The E211 G>A Androgen Receptor Polymorphism Is Associated With a Decreased Risk of Metastatic Prostate Cancer and Androgenetic Alopecia

The E211 G>A Androgen Receptor Polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia, according to a study published in Cancer Epidemiology Biomarkers & Prevention in 2005. The study found that men with the E211 G>A polymorphism had a lower risk of developing metastatic prostate cancer and androgenetic alopecia compared to those without the polymorphism. The study included 1,056 men with prostate cancer and 1,267 controls. The study suggests that further investigation is needed to determine whether these associations can be attributed to linkage to one or both of the functional repeat sequences at the same loci.